Metilprednizolon Teva (Methylprednisolone)

Methylprednisolone binds to intracellular glucocorticoid receptors, forming a complex that moves into the cell nucleus. This complex modifies gene transcription, increasing anti‑inflammatory protein production while suppressing pro‑inflammatory cytokines, adhesion molecules, and enzymes, thereby reducing inflammation and immune system activity.

The dosage of Metilprednizolon Teva is individualized. A qualified prescriber determines the appropriate amount, frequency, and duration based on the patient’s condition, severity, weight, and response to therapy. Dosing information is provided on the prescription and accompanying product labeling.

Safety data for methylprednisolone in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant. Healthcare providers will evaluate the risk‑benefit profile for each patient and advise accordingly.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where needed), and necessary import documentation.

Methylprednisolone offers a potent anti‑inflammatory effect with a relatively rapid onset when given intravenously, making it suitable for acute severe conditions. Compared with dexamethasone or prednisone, it provides a higher glucocorticoid potency per milligram, allowing lower volumes for IV administration while achieving comparable therapeutic outcomes.

Metilprednizolon Teva should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect from light, and avoid freezing or shaking the solution. Do not use the product if it appears discolored or contains particles.

The product is supplied as an injectable solution for intravenous infusion. Administration is performed by a qualified healthcare professional, typically over a short period (minutes to hours) depending on the indication and prescribed dose. Infusion rates and dilution instructions are detailed in the product’s prescribing information.

Serious risks include adrenal suppression leading to crisis on abrupt discontinuation, severe infections due to immunosuppression, osteonecrosis of bone, psychiatric disturbances such as psychosis, and cardiovascular complications like hypertension or arrhythmias. Patients should be monitored closely for these events, especially during high‑dose or prolonged therapy.

Metilprednizolon Teva is contraindicated in patients with known hypersensitivity to methylprednisolone or any formulation component, and in those with systemic fungal infections unless appropriate antifungal therapy is administered. Caution is also advised for individuals with uncontrolled diabetes, active peptic ulcer disease, or severe psychiatric disorders.